Patents by Inventor Neil J Press

Neil J Press has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidinium derivatives as M3 muscarnic receptor antagonists
    Patent number: 8383625
    Abstract: Compounds of formula (I) in salt or zwitterionic form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: February 26, 2013
    Assignee: Novartis AG
    Inventors: Neil J Press, Collingwood P Stephen
  • Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists
    Patent number: 8084463
    Abstract: Compounds of Formula (I); in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: December 27, 2011
    Assignee: Novartis AG
    Inventors: Neil J Press, Stephen P Collingwood, Urs Baettig, Brian Cox, Sudhakar D Garad, Hyungchul Kim, Dimitris Papoutsakis, Simon J Watson
  • Organic compounds
    Publication number: 20090298824
    Abstract: Compounds of formula I in free or salt form, where Y, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the CXCR2 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: January 20, 2005
    Publication date: December 3, 2009
    Inventors: Neil J. Press, David Porter, Catherine Leblanc, Clive McCarthy, Nicolas Soldermann, Lyndon N. Brown
  • PYRROLINIDIUM DERIVATIVES AS M3 MUSCARINIC RECEPTORS
    Publication number: 20090291960
    Abstract: Compounds of formula (I) in salt or zwitterionic form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: December 22, 2005
    Publication date: November 26, 2009
    Inventors: Neil J. Press, Collingwood P. Stephen
  • Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (PDE4) inhibitors
    Patent number: 7273875
    Abstract: The invention relates to compounds of formula I in free or salt form, where R1 is a monovalent aromatic group having up to 10 carbon atoms, and R2 is a cycloaliphatic group having up to 8 ring carbon atoms. Compositions containing them, methods for their preparation and their use as pharmaceuticals are also described.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: September 25, 2007
    Assignee: Novartis AG
    Inventors: Alastair Denholm, Thomas H Keller, Clive McCarthy, Neil J Press, Roger J Taylor
  • Aminothaizoles and their use as adenosine receptor antagonists
    Patent number: 7109202
    Abstract: Compounds of formula (I) in free or salt form, where A is a C6-C15 monovalent aromatic group. R1 is hydrogen, phenyl optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, C1–C8-alkyl, C1–C8-haloalkyl, C1–C8-alkoxy, C1–C8-alkoxy-C1–C8-alkyl or acyloxy, or a 5- or 6-membered monovalent heterocyclic group, R2 is hydrogen, C1-C8-alkyl, acyl or CON(R3)R4, provided that R2 is C1–C8-alkyl, acyl or CON(R3)R4 when R1 is hydrogen, R3 and R4 are each independently hydrogen, or C1–C8-alkyl, together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, and Zl, Z2, Z3 and Z4 are each independently N or CR5, at least one of them being CR5, and R5 is hydrogen, C1–C8-alkyl or C1–C8-alkoxy.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: September 19, 2006
    Assignee: Novartis AG
    Inventors: Neil J Press, Roger J Taylor